Targeting the renin-angiotensin system and optimizing tacrolimus exposure are both postulated to improve outcomes in renal transplant recipients (RTRs) by preventing interstitial fibrosis/tubular atrophy (IF/TA). In this multicenter, prospective, openlabel controlled trial, adult de novo RTRs were randomized in a 2 × 2 design to low-vs This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
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and other studies suggests that immunological events account for most allograft losses and have brought into question the association between IF/TA and adverse outcomes. [13] [14] [15] [16] Indeed, newer analyses indicate that IF/TA with inflammation (IF/TA+i) 15 is more deleterious to the graft than is IF/TA alone. [17] [18] [19] [20] However, little is known about clinical interventions that can prevent or reverse IF/TA+i.
Reduced tacrolimus exposure has been associated with better allograft function, less IF/TA, and reduced prevalence of polyomavirus viremia. However, it has also been associated with a greater incidence of rejection, relative to standard tacrolimus dosing, 6 by permitting allograft-specific T cell activation, T cell-mediated rejection (TCMR), donor-specific antibody (DSA) development 21 and, ultimately, antibody-mediated rejection (AMR). 18, 22, 23 Another approach proposed to improve clinical outcomes in RTRs is treatment with blockers of the renin-angiotensin system (RAS), namely antihypertensive therapy (AHT) of the angiotensin-converting enzyme inhibitor or angiotensin II receptor 1 blocker classes (ACEi/ ARBs). Independent of their vasodilatory effects, these RAS-targeting
AHTs are anti-inflammatory and immunomodulating, 24, 25 and they appear to block histopathologic change in renal allografts. 26, 27 As with reduced-dose tacrolimus, clinical evidence supporting the use of ACEi/ARBs in RTRs is ambiguous, although they are used to limit systemic inflammation and renal fibrosis in glomerulonephritis, 28 hypertensive injury, and other pathologic states. 29 In a post hoc analysis of trial data, ACEi/ARB use was independently associated with protection from IF/TA at 24 months. 30 A recent study of RTRs with proteinuria showed that ACEi use had no significant effect on renal function or patient survival. 31 Moreover, despite some promising preclinical 32 and clinical 33, 34 findings, ACEi/ARBs have shown no consistent patient or allograft survival benefit after meta-analysis. 35 This study (FKC-014) was designed to address these uncertainties by assessing the effects on IF/TA prevalence of 2 different interventions: a reduced tacrolimus dosing strategy and use of RASblocking AHTs.
standard-dose (LOW vs STD) prolonged-release tacrolimus and to angiotensin-con- Practice, the International Conference on Harmonisation guidelines, and applicable laws and regulations. An independent ethics committee from each study center granted approval before initiation.
Written informed consent was obtained from each patient before enrollment into the study. 
| Endpoints
There For the primary and secondary endpoints, treatment effects were assessed in a pairwise fashion between intervention groups; in other analyses, comparisons were made across the 4 treatment groups. before and 4 days after implantation), steroids (200-500 mg intravenous methylprednisolone preoperatively followed by either methylprednisolone intravenously or prednisone orally, starting at 1 mg/kg and tapering to ≥ 5 mg daily by month 5), and mycophenolate mofetil (MMF; 1 g twice daily from day 1 posttransplant, with adjustment as clinically indicated).
| Treatments
Prolonged-release tacrolimus was initiated in the STD intervention group as a single dose of 0.15-0.20 mg/kg, with dose adjustments as needed to achieve the target trough concentrations of 12 ± 2 ng/mL for weeks 1 and 2, 10 ± 2 ng/mL for week 3 through month 3, and 8 ± 2 ng/mL for month 4 through month 6. For patients randomized to the LOW group, the initial dose was 0.05-0.15 mg/kg, adjusted thereafter to achieve a target trough concentration of 5 ± 1 ng/mL through month 6. Tacrolimus trough targets and dosing after month 6 were at the Investigator's discretion for all patients.
Patients randomized to the ACEi/ARB intervention group received ramipril (initially 5 mg/day, increasing to 10 mg/day by month 3 posttransplant), or irbesartan (150 mg/day, increasing to 300 mg/day) by month 1 posttransplant, continuing to month 24. For patients randomized to the OAHT intervention group, non-ACEi/ARB-based antihypertensive therapy was initiated if the patients became hypertensive.
| Procedures
Renal biopsies were performed per protocol at baseline, month 6, and month 24 to assess the coprimary efficacy endpoints (ie, pres- 
| Statistical analysis
The sample size of 240 evaluable patients was based on a statistical power of 80% to detect a 15% difference in IF/TA prevalence between 2 groups, using a .05 significance level and 2-tailed test.
Tacrolimus trough concentrations were estimated using 4 piecewise, mixed-effects models corresponding to the 4 sets of dosing guidelines. Each model used log tacrolimus concentration as the response with fixed effects of time, dosing group, and interaction (between time and dosing group) and a random effect for withinpatient assessments.
ACEi/ARB use, steroid dose, and MMF dose were assessed for each nominal time period in the full analysis set (FAS).
For the coprimary endpoints, logistic regression was used to as- 
| RE SULTS

| Patients
The intent-to-treat (ITT) population included 281 adult de novo RTRs at 13 Canadian study centers. Of these patients, 235 Table S1 ).
For-cause biopsy rates in each treatment group are shown in Table   S2 . Mean patient age was 50.3 years, and 68% were male. Donor age was >50 years in 41.6%; the donor was deceased in 60.9% and identified as an extended criteria donor (ECD) in 21.4% of cases.
Baseline characteristics, including stratification factors (recipient sex, donor age and status, and DGF) and other parameters, were generally well distributed among the 4 treatment groups. However, diabetic nephropathy was more common in patients randomized to the STD + OAHT treatment group than in the general ITT population (27.1% vs 18.1%). In addition, the LOW + OAHT treatment group had a lower rate of DGF than the ITT population (18.8% vs 24.2%). Other baseline differences included imbalances in the proportion of patients with ECDs (more common in the ACEi/ARB intervention group) and with donors who died from cerebrovascular accident (more common in the STD intervention group) ( Table 1 and data not shown).
| Dosing of immunosuppressive therapies and AHTs
Prolonged-release tacrolimus doses administered in each treatment group throughout the study period are summarized in Table S3 All patients received steroid treatment during the study. Mean oral prednisone dose declined from ~30 mg daily in the first 2 weeks posttransplant to <10 mg daily from month 3 to month 24; however, a higher mean dose of prednisone between months 13 and 24 was used in the LOW + OAHT treatment group, compared with the other 3 groups (Table S4 ). MMF dosing was therapeutically similar across treatment groups from transplant to month 24 (Table S5) .
Use of ACEi/ARBs was likewise generally per protocol. In the ACEi/ARB (n = 142) and OAHT (n = 137) intervention groups, ACEi/ ARBs were used in >83% and <16% of patients, respectively, at all times up to month 24. Antihypertensive compliance in each treatment group throughout the study is summarized in (Table S7 ).
In an analysis of patients with biopsies available at months 6 and More detailed histological Banff acute and chronic scores at 6 and 24 months for the 4 treatment groups are shown in Table S8 . Notably, these show a reduced tubulointerstitial and peritubular capillary inflammation in the LOW ACEi/ARB group compared with all other groups, and a similar degree of arteriolar hyalinosis for all groups at 24 months.
| Immunologic events
Rejection events were observed in protocol and for-cause biopsies over 24 months posttransplant. Time to first TCMR of Banff grade F I G U R E 3 Least-squares mean (±standard error) tacrolimus trough concentrations by time for patients randomized to standard-dose (STD) vs low-dose (LOW) tacrolimus (Tac). Light and dark purple shading indicate protocolspecified target trough concentrations for patients randomized to LOW Tac and STD Tac. After month 6, no target was specified. Trough concentrations were estimated from a 4-period mixed model De novo DSA formation was identified in a small number of patients in all treatment groups at months 6 and 24 (Table 2 ). In were reported for all 4 treatment groups (data not shown).
| Polyomavirus activation
Polyomavirus viremia was detected in all treatment groups from month 3 through month 12. By month 6, the prevalence of viremia was significantly reduced in the LOW vs STD intervention group (6.4% vs 16.3%; P = .028), whereas use of an ACEi/ ARB had no effect on prevalence of viremia. After month 6, viremia remained detectable in 4.8%-9.1% of patients across treatment groups. Viral load decreased over time, with 27 (93%) of 29 viremic patients at month 3, but only 7 (50%) of 14 at month 12, carrying >2000 copies/mL of the viral genome (data not shown). 
| Clinical outcomes and patient safety
Renal function, as assessed by eGFR using the Chronic Kidney Disease Epidemiology Collaboration formula, was stable over time from month 1 to month 24 in all treatment groups ( Figure 9 ). Mean diastolic and systolic blood pressures were likewise stable from month 1 to 24 and did not differ across treatment groups ( Figure 10 ). Treatment-emergent adverse events (TEAEs) were observed in nearly all patients in all treatment groups, consistent with expectations for an RTR patient population and the medications mandated in this trial. Serious TEAEs occurred in 64% of patients (Table 3) . TEAEs with a prevalence of ≥10% during the study are presented in Table S9 . Over the 24 months, there were 11 instances of graft loss and 3 deaths (embolic stroke, infective endocarditis, and unknown cause). Overall, 90% of patients randomized to ACEi/ARB remained on this treatment for the duration of the study.
| D ISCUSS I ON
The prevalence of IF/TA ≥2 in FKC-014 was similar for the LOW and STD tacrolimus intervention groups at month 6 and for the ACEi/ARB and OAHT intervention groups at month 24, findings that represent the 2 coprimary objectives of this study. Of particular interest, however, was the observation that ACEi/ARB use reduced IF/TA progression in the context of reduced exposure to prolonged-release tacrolimus and that the IF/TA grade was lower in this group compared with all others. RAS blockade also abrogated the heightened rejection risk otherwise observed with LOW tacrolimus. These findings suggest a potentially important interaction between the 2 interventions tested in this study.
IF/TA observed during the first year after transplant has been associated with late graft loss or other adverse outcomes, 38, 39 particularly when other markers of allograft injury are evident as well. 26, 40 Recently, several studies have highlighted the prognostic significance of an inflammatory infiltrate, either alone (Banff i score) 18, 41 or Mean diastolic blood pressure (mmHg) Limitations include the fact that histopathologic comparisons were statistically underpowered, due to a higher-than-expected number of allograft biopsies being unavailable or inadequate. However, the coprimary endpoints of this study (IF/TA comparisons at month 6 and at month 24) are unlikely to have been substantially affected by this loss of statistical power, given the relative differences between groups.
Another limitation is the nonuniform distribution of risk-associated baseline characteristics across treatment groups, including DGF and use of ECD organs. In addition, the current analysis was restricted to surrogate markers; clinical outcomes such as allograft and patient survival will be reported upon study completion at Year 5. A meaningful analysis of de novo DSA formation was precluded by the low number of patients that developed DSA by 24 months posttransplant.
It is unclear whether the interaction observed in this trial between tacrolimus dose and RAS-blocking AHTs can be generalized to other RTR patient populations or other immunosuppressive protocols. However, it is reassuring to compare the present findings with those in a recent European study examining the effects of CNI dose-minimization. 48 As in the current study, Gatault and coworkers used basiliximab (Simulect ® , Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada) induction and prolonged-release tacrolimus for maintenance immunosuppression. In contrast to the current study, these authors aimed for steroid-free maintenance for most of their RTRs. Because AHT use was not reported in their study, findings can only be compared with FKC-014 data in the OAHT intervention group. With this restriction, some striking parallels emerge between the 2 studies, particularly related to the elevated risk of rejection and higher rates of IF/TA+i in patients receiving lower-dose tacrolimus. 48 Increased risk of rejection has also been reported in patients using immediate-release tacrolimus whose tacrolimus exposure over 6 months was similar to that of the LOW group in the present study. and the staff of the various study sites is gratefully acknowledged. 
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